Yang Cao - Sep 19, 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Regulatory Officer
Signature
/s/ Yang Cao by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Sep 19, 2022
Transactions value $
$0
Form type
4
Date filed
9/20/2022, 04:09 PM
Next filing
Dec 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +145K $0.00 145K Sep 19, 2022 Common Stock 145K $3.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026.